Columbus Circle Investors’s Sarepta Therapeutics SRPT Stock Holding History

Columbus Circle Investors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-242,889	Closed	-$36.9M	–	181
2019 Q2	$36.9M	Sell	242,889 -149,354	-38%	-$18.2M	0.99%	46
2019 Q1	$46.8M	Buy	392,243 +143,552	+58%	+$18.5M	1.19%	24
2018 Q4	$27.1M	Buy	248,691 +177,930	+251%	+$22.3M	0.77%	55
2018 Q3	$11.4M	Buy	70,761 +43,989	+164%	+$6.01M	0.23%	127
2018 Q2	$3.54M	Buy	+26,772	New	+$2.52M	0.07%	170
2017 Q4	–	Sell	-121,758	Closed	-$5.46M	–	261
2017 Q3	$5.46M	Buy	121,758 +73,395	+152%	+$2.93M	0.09%	165
2017 Q2	$1.63M	Buy	48,363 +14,336	+42%	+$467K	0.03%	213
2017 Q1	$1.01M	Buy	34,027 +21,652	+175%	+$670K	0.01%	247
2016 Q4	$339K	Buy	+12,375	New	+$497K	﹤0.01%	250

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Columbus Circle Investors's SRPT Position: Q3 2019 in Review

Columbus Circle Investors sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 242,889 shares — an estimated $36.9M sold.

Columbus Circle Investors first reported a position in SRPT in Q4 2016 and held it in 9 quarters. The position peaked at $46.8M in Q1 2019. 340 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

Columbus Circle Investors reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
Columbus Circle Investors sold 242,889 Sarepta Therapeutics shares in Q3 2019, an estimated $36.9M.
Columbus Circle Investors first reported a position in Sarepta Therapeutics in Q4 2016 and held it in 9 quarters.
Columbus Circle Investors's Sarepta Therapeutics position peaked at $46.8M in Q1 2019.
340 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on Columbus Circle Investors's 13F filing for Q3 2019, filed 29 Oct 2019.